Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Molecular pathways and targeted therapy in cholangiocarcinoma. Clin Adv Hematol Oncol 2019 Nov;17(11):630-637

Date

12/19/2019

Pubmed ID

31851165

Scopus ID

2-s2.0-85074712470 (requires institutional sign-in at Scopus site)   17 Citations

Abstract

Cholangiocarcinoma (CCA) encompasses a rare group of malignancies arising from epithelial cells lining the biliary tree that connects the liver and gallbladder to the small intestine. Most patients present with advanced incurable disease that has a poor prognosis, and standard treatment options remain limited. Effective nontoxic treatment options for advanced CCA are needed. Fibroblast growth factors (FGFs) and their fibroblast growth factor receptor (FGFR) pathways are crucial to cellular proliferation, cellular survival, and differentiation of many malignancies, but are especially relevant in CCA. The targeting of FGF/FGFR has become the most promising approach to treating patients with advanced/metastatic CCA. Here we review CCA, and discuss the promise of FGFR-directed therapy in advanced CCA.

Author List

Dabney RS, Khalife M, Shahid K, Phan AT

Author

Alexandria T. Phan MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Bile Duct Neoplasms
Cholangiocarcinoma
Clinical Trials as Topic
Humans
Molecular Targeted Therapy
Receptors, Fibroblast Growth Factor
Treatment Outcome